Trial Profile
A 3-way, Crossover, Randomized, Open-label Study in Healthy Subjects Comparing the Bioavailability of Belumosudil (KD025) Tablets in Fed and Fasted States and Relative Bioavailability of Tablets and Capsules in the Fed State
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Kadmon Corporation
- 13 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Sep 2015 New trial record